|Bid||8.05 x 900|
|Ask||8.07 x 1300|
|Day's Range||7.21 - 8.82|
|52 Week Range||2.75 - 16.47|
|Beta (3Y Monthly)||4.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.67|
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
I've been keeping an eye on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) because I'm attracted to its fundamentals...
Zynerba, an actively-traded, micro-cap pharma company that develops synthetic cannabinoid therapies targeting rare and near-rare neuropsychiatric disorders, announced positive top-line results from the open-label Phase 2 BELIEVE 1 study that is evaluating the safety and efficacy of Zygel, codenamed ZYN002, in developmental and epileptic encephalopathies, or DEE. Zygel is administered as a transdermal gel to children and adolescents with DEE. Top-line results showed 46 patients in the modified intention to treat, or ITT, population, who had more debilitating type of seizures, experienced a more than 44% mean reduction in seizures frrm month two onward using monthly seizure frequency normalized to 28 days.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the open label Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial. The trial assessed the safety and efficacy of Zygel in developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare pediatric epilepsy syndromes, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). DEE is characterized by the presence of multiple focal and generalized seizure types and severe cognitive and behavioral impairment.
One of my favorite things about being a financial writer is that I have the opportunity to present lesser-known but compelling investments to the public. As I see it, Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock is one of those hidden gems that most people simply aren't aware of, but ought to be. Timing could also be right, as short-sellers have driven ZYNE stock down almost 6% in the last week.It's also an entry point into eternally buzz-worthy cannabis stocks, and you might call it "investing with a conscience" as a with position in ZYNE stock, you could be supporting a company with the potential to make people's lives better -- a nice added bonus for those of us who prefer to live and invest in a better world. Benefiting Patients and ShareholdersIt's important to "know what you own" -- as I always like to say -- so first things first: let's understand what this little cannabis company's all about. Zynerba describes its mission as "to develop next-generation transdermally delivered cannabinoid therapeutics" with the objective of addressing "significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese conditions might hit home for you and your family, as they include autism, epilepsy, and a somewhat rare neuropsychiatric condition known as Fragile X syndrome. Whereas the idea of combating the symptoms of these conditions with cannabis-based solutions was unthinkable when I was young, it's now just a matter of time before these solutions come to light and in some cases, FDA approval is the only thing standing in the way. * 10 Stocks to Sell in Market-Cursed September While Zynerba has a number of products in its clinical pipeline, the company's flagship product candidate, Zygel, is by far the best-known of the potential medical game changers. It's described by the company, as "the first and only pharmaceutically produced CBD … formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system" and is intended to alleviate some of the symptoms associated with Fragile X syndrome (which can cause cognitive impairment and/or learning disabilities), pediatric autism, and some forms of epilepsy. Progress for Hopeful Patients … and Welcome News for ZYNE Stock InvestorsIt's seldom that you'll find a fast-moving timeline when it comes to FDA approval, but many Zynerba stock investors have been pleasantly surprised with the progress that Zygel has been making through the regulatory process. Patients and ZYNE shareholders alike were undoubtedly pleased when Zynerba's chairman and CEO, Armando Anido, announced in May that Phase 2 trials were under way for Zygel as a treatment for autism spectrum disorder:"We are excited to initiate the BRIGHT trial evaluating the role of Zygel in ASD and are hopeful that Zygel may improve some of the core social and behavioral symptoms of ASD. We look forward to presenting topline data in the first half of 2020."This was also the time when the company had selected Zygel as the name of its ZYN002 CBD-based transdermal gel, which remains the company's most important potential product. But that was only the beginning of the journey: by May, the FDA had granted the highly coveted fast-track designation to Zygel for the treatment of Fragile X syndrome, which has been cited as a known form of attention deficit disorder as well as inherited learning disabilities.As you might expect, the market celebrated that day and sent the ZYNE stock price northward to the tune of 9.5%. Not only were they celebrating the fast-track designation, but also Zynerba's statement that data on Zygel trials was to be "expected in the second half of 2019." * 7 Tech Stocks You Should Avoid Now By August, Zynerba had proudly released the data from a 12-week study of Zygel in the treatment of symptoms of Fragile X syndrome. While encouraging, the results did admittedly have limitations:"[T]he results from this open-label trial indicate that ZYN002 may be an effective treatment for many behavioral and emotional symptoms associated with FXS although the study's findings are limited by the open label design and small sample size."Clearly there's a need for further testing, but the preliminary results are heartening and ought to provide some hope for patients who may be amenable to CBD-based treatment. Takeaway on Zynerba StockIn this analysis of Zynerba and ZYNE stock, I deliberately spent less time focusing on price charts and analyst expectations. Instead, I wanted to paint a picture of a company that's truly making a difference in the medical community; by investing in Zynerba stock, you're making a bold statement in favor of the future of CBD as a vehicle of profits, sure, but also as a source of hope for patients worldwide.As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About appeared first on InvestorPlace.
After a weak couple of months, cannabis stocks rallied in the first week of September . That rally seems to have stalled so far in the second week of the month. S3 Partners analyst Ihor Dusaniwsy said ...
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at two upcoming conferences in New York City. A live webcast of the presentations will be accessible on the Investor Relations page of http://www.zynerba.com.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium. The meeting is being held at Aston University in Birmingham, UK on September 4th through 6th, 2019. This poster will describe information evaluating the Social Avoidance, Irritability, and Socially Unresponsive/Lethargic subscales of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) in relation to the experience of caregivers caring for a child with Fragile X syndrome (FXS).
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, respectively. From an economic perspective, the unemployment levels and interest rates have remained low, which helped boost share prices. That being said, the market isn’t immune to the recent dramas that have unfolded. The ongoing trade war with China and weak global growth have raised red flags among investors that a recession could be on the way, with those fears causing widespread volatility.However, analysts are telling investors not to panic. Wall Street analysts believe that healthcare stocks still represent compelling investment opportunities amid economic uncertainty.Using TipRanks powerful stock screener, we set out to pinpoint three stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, we selected filters for healthcare stocks with a “strong buy” consensus ratings. We also specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target.Now let’s delve into these three top healthcare stocks and see if they really have what it takes to fight off the market flu: Novavax Inc. (NVAX)The first healthcare company on our list develops vaccines that target respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV).Novavax has riled up Wall Street last week with enticing Phase III ResVax trial results. The data presented at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) on August 12 showed that the company's ResVax vaccine was able to protect infants one year after birth from all causes of pneumonia, including RSV associated pneumonia. It also highlighted the fact that protecting infants from the RSV infection can protect infants from contracting an infection from other microbes.Investors have more reasons to be excited about the vaccine maker. On August 5, NVAX reached an agreement with the FDA on its Phase 3 trial design for Nanoflu, its seasonal influenza vaccine for adults 65 years and older. The company also partnered with Catalent Biologics (CTLT) back in June, allowing CTLT to expand its gene therapy footprint with the acquisition of Novavax’s manufacturing assets and capabilities.B.Riley FBR analyst George Zavoico remains bullish on NVAX with a Buy rating, and his $35 price target, which seems like wishful thinking, may get another boost: “Based on these new results and other recent events, we place our price target for Novavax under review as we update our financial model of the company.” (To watch Zavoico's track record, click here)"We do not believe these new, positive results will lead the FDA to reconsider its decision to require another Phase III trial of ResVax by maternal immunization before considering a BLA filing. While we still forecast that the European Medicines Agency (EMA) is likely to agree with the FDA on this point, we would not be surprised if, due partly to these new results, the EMA may decide to allow Novavax to file a marketing authorization application (MAA) for ResVax while also requiring a post-marketing efficacy trial to confirm the results. A decision is expected this fall," Zavoico opined.All in all, the rest of the Street mirrors the analysts’ bullish sentiment. NVAX has a ‘Strong Buy’ analyst consensus and a $29.88 average price target, implying ~281% upside potential from current levels. (See NVAX’s price targets and analyst ratings on TipRanks) Amarin Corporation (AMRN)It’s no secret that Wall Street analysts like Amarin stock. It has a ‘Strong Buy’ analyst consensus and a ~$32 average price target, suggesting over 100% upside potential from current levels. (See AMRN’s price targets and analyst ratings on TipRanks)Investors were caught by surprise recently after Amarin announced the FDA’s notice of plans to hold an advisory committee (AdCom) on the sNDA for its Vascepa drug.4-star Roth Capital analyst Yasmeen Rahimi argues that the AdCom might work in AMRN’s favor.While the news comes as a shock given how close AMRN is to its September 28 priority-review PDUFA for Vascepa, management stated in May that they believed an AdCom was likely as they are seeking a Vascepa label extension. As such, the AdCom gives AMRN a platform to defend its label extension as well as highlight Vascepa’s ability to reduce cardiovascular related events and deaths, its superior safety and its support from the medical community.“AdCom allows for Vascepa discussion in a public forum, increasing awareness and transparency on key issues, and puts all this info just a click away for potential future Vascepa-prescribers to find and digest,” Rahimi opined, as she reiterates her Buy rating and $31 price target on Amarin stock."In totality, we believe AMRN is primed to make a strong case to the FDA and can turn this AdCom into a highlight reel of the CV benefits Vascepa offers patients," the analyst concluded. (To watch Rahimi's track record, click here) Zynerba Pharmaceuticals (ZYNE)Zynerba develops innovative therapies to treat Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).Investment firm Canaccord Genuity has hosted Zynerba at its annual growth conference the day after its second quarter earnings release in which the company altered some timelines for its data readouts. Lead analyst Sumant Kulkarni believes the company is still cautiously optimistic regarding its Zygel (cannabidiol gel) in Fragile X syndrome (FXS). While its Zygel trial enrollment continues, the company hasn’t provided an end date for enrollment. ZYNE does remain confident that Zygel use in DEE treatment can deliver an adequate dose of CBD via the transdermal route.The analyst points out that an Epidiolex CBD solution for Lennox-Gastaut/Dravet syndromesits has already been released by its competitor, GW Pharmaceuticals (GWPH). Not to mention GWPH’s market cap is $5 billion versus ZYNE’s $250 million. However, Kulkarni argues that this disparity represents a unique buying opportunity.Based on all of the above factors, Kulkarni reiterates his Buy rating and $18 price target on ZYNE stock, which implies about 60% upside from current levels.Kulkarni is certainly not the first analyst with an optimistic outlook for the biotech firm, as TipRanks analytics showcasing ZYNE stock as a Strong Buy. With an average price target of $22, analysts are predicting an upside of nearly 100%. In total, the stock has received 4 'buy' ratings in the last three months. (See ZYNE’s price targets and analyst ratings on TipRanks)
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty...
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial. This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). “Fragile X is a family diagnosis, impacting not only the diagnosed child but also the entire family unit,” said Honey Heussler, MBBS, FRACP, MRCPCH, PGCAP, DM, Associate Professor, University of Queensland and Medical Director Child Development, Children’s Health Queensland, and an investigator in the FAB-C study.
DEVON, Pa., Aug. 06, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Jim Cramer is wary of Zynerba Pharmaceuticals . "No. If you want this, you want GW Pharmaceuticals ," said Cramer to a caller during the Lightning Round of his "Mad Money" program on Monday. In this daily bar chart of ZYNE, below, we can see that prices quietly bottomed around $3 in late December.
On Monday's “Mad Money,” Jim Cramer said he remains bearish on Range Resources Corp. (NYSE: RRC ) saying natural gas is the weakest part of the petrol chain. Cramer says although it's speculative, he is ...
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $11.87, marking a +1.63% move from the previous day.